Indira Turney, an associate research scientist in the Department of Neurology, is studying how lived experiences affect they way the brain ages in diverse populations.
Even in people with complete paralysis after spinal cord injury, some nerves fibers are preserved. A Columbia physician-scientist is developing a new way to salvage those fibers and restore movement.
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.
Based on Columbia research, an experimental drug for a rare type of ALS is being tested in a phase 3 clinical trial after a new study found that the drug lowered levels of a toxic protein.
Since 1955, “Merritt’s Neurology,” edited by Columbia neurologists, has been regarded as the standard reference work in the field. James Noble, MD, joins the ranks for the latest edition.
New technology will allow scientists to uncover what happens in the brain during the early stages of Parkinson's disease, which could lead to earlier diagnosis and better therapies for the disease.